Publication date: Jul 09, 2025
If patients responded to the treatment, they continued on nivolumab alone every four weeks for up to 30 cycles (or two years). Researchers measured both treated tumors and untreated tumors. In is also a member of the IGNYTE trial steering committee and one of the lead investigators on the trial. In is optimistic about the future of RP1 therapy. In heading up the site.
| Concepts | Keywords |
|---|---|
| Administeredpatients | Advanced |
| Cancer | Body |
| Trialdisclosure | Clinical |
| Untreatable | Dr |
| Fight | |
| Ignyte | |
| Immunotherapy | |
| Injected | |
| Keck | |
| Melanoma | |
| Nivolumab | |
| Rp1 | |
| Trial | |
| Tumor | |
| Tumors |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | second cancer |
| drug | DRUGBANK | Spinosad |
| disease | MESH | Cancer |
| drug | DRUGBANK | Nivolumab |
| pathway | REACTOME | Immune System |
| disease | MESH | skin cancer |
| disease | MESH | cold sores |
| pathway | KEGG | Melanoma |
| disease | MESH | melanoma |
Original Article
(Visited 3 times, 1 visits today)